Optimal timing of surgery after chemoradiation for advanced rectal cancer: Preliminary results of a multicenter, nonrandomized phase II prospective trial

Annals of Surgery

Volumn 254, Issue 1, 2011, Pages 97-102

  Garcia Aguilar, Julio ^a   Smith, David D ^b   Avila, Karin ^a   Bergsland, Emily K ^c   Chu, Peiguo ^a   Krieg, Richard M ^d  

^a City of Hope ^*  (United States)

^b Division of Biostatistics   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; ATELECTASIS; BOLUS INJECTION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL PAIN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTUM CANCER; SMALL INTESTINE OBSTRUCTION; SURGICAL INFECTION; URINARY TRACT INFECTION; URINE RETENTION; VASCULAR DISEASE;

FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECTAL NEOPLASMS; TIME FACTORS;

EID: 79959511682     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182196e1f     Document Type: Article

References (22)

1. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17): 1731-1740.
2. Maas M, Nelemans PJ, Valentino V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9): 835-844.
3. O'Neill BD, Brown G, Heald RJ, et al. Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol. 2007;8(7): 625-633. (Pubitemid 47008889)
4. Wang Y, Cummings B, Catton P, et al. Primary radical external beam radiotherapy of rectal adenocarcinoma: long term outcome of 271 patients. Radiother Oncol. 2005;77(2):126-132. (Pubitemid 41682376)
5. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10. (Pubitemid 19099520)
6. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumor assessment. Eur J Cancer. 2006;42(8):1031-1039.
7. Jass JR, O'Brien MJ, Riddell RH, et al. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Association of Directors of Anatomic and Surgical Pathology. Hum Pathol. 2007;38(4):537-545.
8. Edge SB, Byrd DR, Compton CC, et al. eds. AJCC Cancer Staging Manual (ed 7). New York, NY, Springer, 2010.
9. Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2): 187-196.
10. Tulchinsky H, Shmueli E, Figer A, et al. An interval >7 weeks between neoad-juvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008;15(10):2661-2667.
11. Moore HG, Gittleman MD, Minsky B. et al. Rate of Pathologic complete response with increased interval between preoperative combine modality therapy and rectal cancer resection. Dis Colon Rectum. 2004;47(3):279-286. (Pubitemid 38280578)
12. Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582-589.
13. Stein DE, Mahmoud NN, Anné PR, et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum. 2003;46(4):448-453. (Pubitemid 36428037)
14. Dolinsky CM, Mahmoud NN, Mick R, et al. Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. J Surg Oncol. 2007;96(3):207-212. (Pubitemid 350194618)
15. Lim SB, Choi HS, Jeong SY, et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg. 2008;248(2):243-251.
16. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17(8):2396-2402. (Pubitemid 29368238)
17. Glehen O, Chapet O, Adham M, et al. Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer. Br J Surg. 2003;90(8): 996-998. (Pubitemid 37026330)
18. Koeberle D, Burkhard R, von Moos R, et al. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer. 2008;98(7):1204-1209. (Pubitemid 351481682)
19. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11(3): 241-248.
20. Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does delayed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys. 2008;71(4):1181-1188.
21. Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. Br J Surg. 2008;95(12):1534-1540.
22. Supiot S, Bennouna J, Rio E, et al. Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer. Colorectal Dis. 2006;8(5):430-435. (Pubitemid 43676659)